SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Elisabeth of Austria — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientElisabeth of Austria
Date of birth1837-12-24
IdentifiersMRN HR-NI030-SYN-TD; SSN (made up) 000-30-5817
Document date1894-04-28
AuthorAdelheid Marchetti-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Twelve-week review of anorexia nervosa, mood and sertraline. [S]

History of Present Illness

Empress Elisabeth returns eight weeks after her four-week review. She has taken sertraline 50 mg for six weeks; the nurse check two weeks after starting found only mild nausea, which passed. She has kept to the meal plan with the dietitian's help, including by video during a two-week journey, and attends CBT-E weekly. She walks about an hour a day and has not used the gymnastics apparatus. She feels warmer and steadier. Her mood is a little better; she has had no thoughts of death for three weeks. She still dislikes seeing her weight but tolerates the open weighing. [S]

ElementDetail
Sertraline50 mg for six weeks; early nausea passed
TreatmentWeekly CBT-E; dietitian by video while travelling
ExerciseAbout an hour of walking a day
SafetyNo thoughts of death for three weeks

Review of Systems

SystemResultFinding
ConstitutionalNegativeWarmer; more energy
CardiovascularNegativeNo swelling, palpitations or dizziness
GastrointestinalNegativeFullness after meals much less
PsychiatricPositiveMood a little better; PHQ-9 10

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Thiamine 100 mg tablet, one by mouth daily for 14 days, starting before the meal planonce daily for 14 daysOral route1894-02-03 to 1894-02-17completedS
Cholecalciferol 50 microgram (2,000 IU) capsule, one by mouth dailyonce dailyOral route1894-02-03activeS
Phosphorus 250 mg tablet (potassium and sodium phosphates), one by mouth twice daily with meals for three weekstwice daily with mealsOral route1894-02-10 to 1894-03-03completedS
Calcium carbonate 1,250 mg (500 mg elemental calcium) tablet, one by mouth daily with a mealonce daily with a mealOral route1894-03-03activeS
Sertraline 25 mg tablet, one by mouth each morning for two weeksonce daily in the morningOral route1894-03-03 to 1894-03-17completedS
Sertraline 50 mg tablet, one by mouth each morningonce daily in the morningOral route1894-03-17activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1894-04-28Body height172cmS
1894-04-28Body weight52kgS
1894-04-28Body mass index (BMI) [Ratio]17.6kg/m2S
1894-04-28Systolic blood pressure104mm[Hg]S
1894-04-28Diastolic blood pressure66mm[Hg]S
1894-04-28Heart rate60/minS
1894-04-28Respiratory rate14/minS
1894-04-28Body temperature36.4CelS
1894-04-28Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1894-04-28Hemoglobin [Mass/volume] in Blood12.4g/dL12-15.5 g/dLNormalS
1894-04-28Leukocytes [#/volume] in Blood by Automated count4.410*3/uL4-11 10*3/uLNormalS
1894-04-28Sodium [Moles/volume] in Serum or Plasma137mmol/L135-145 mmol/LNormalS
1894-04-28Potassium [Moles/volume] in Serum or Plasma4mmol/L3.5-5.1 mmol/LNormalS
1894-04-28Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.7-2.2 mg/dLNormalS
1894-04-28Phosphate [Mass/volume] in Serum or Plasma3.4mg/dL2.5-4.5 mg/dLNormalS
1894-04-28Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma30U/L7-35 U/LNormalS
1894-04-28Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]10{score}S

Physical Exam

Vital signs recorded on 1894-04-28; see the Vital Signs section. [S]

SystemFinding
GeneralThin; weight 52.0 kg, BMI 17.6; temperature 36.4 C
CardiovascularSeated blood pressure 104/66, pulse 60; no orthostatic change; no edema
PsychiatricCalmer; mood mildly low; no intent or plan to harm herself

Problems

ProblemClinical statusVerificationCodeProvenance
Weight loss to a body mass index of 16.0 (47.4 kg at 172 cm), about 6 kg over six months, with fatigue, swelling of both ankles, dizziness on standing, slow pulse and cold intolerance; cause not established at intake; a restrictive eating disorder suspected, with thyroid disease, celiac disease, diabetes, malignancy and adrenal insufficiency to be excluded; eating disorders psychiatry consultation requestedresolvedconfirmed R63.4S — Synthetic presenting problem anchored to her documented restrictive eating, low weight and swelling; superseded by the diagnosis at the consultation.
Anorexia nervosa, restricting type, moderate (DSM-5-TR), with compulsive exercise and frequent self-weighing, beginning in early adulthood; complicated at diagnosis by sinus bradycardia, orthostatic dizziness, ankle edema, mild anemia and leukopenia, low glucose, raised ALT and low phosphate after refeeding beganactiveconfirmed F50.011S — Synthetic modern diagnosis made at the consultation, linked to her documented restrictive eating and exercise and to the retrospective diagnosis of anorexia nervosa (R).
Major depressive disorder, recurrent, moderate, with persistent grief for her son, who died five years ago; passive thoughts of death without intent or plan at intakeactiveconfirmed F33.1S — Synthetic modern diagnosis linked to her documented mourning and ever-deepening depressions; not a claim that she was so diagnosed.
Low bone mass (osteopenia) of the lumbar spine and hip after decades of low weight: lumbar spine T-score -2.1, femoral neck T-score -1.8; FRAX 10-year probabilities 6.8% for a major osteoporotic fracture and 1.2% for hip fracture; no fracturesactiveconfirmed M85.80S — Synthetic modern finding on DXA; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationWeight and BMI (open weighing in the consulting room)Weekly at first, then every visitCompleted today52.0 kg, BMI 17.6; up 2.4 kg in eight weeks
ExaminationOrthostatic pulse and blood pressure, and temperatureEvery visitCompleted todayPulse 60, blood pressure 104/66, no orthostatic change; temperature 36.4 C
LaboratorySodium, potassium, phosphate, magnesium and glucoseBaseline; three to four days after nutrition starts; weekly for the first weeks; then at each visit while underweightCompleted todaySodium 137, potassium 4.0 mmol/L, phosphate 3.4 mg/dL, magnesium 2.0 mg/dL
LaboratoryBlood count and liver enzymesBaseline; repeat when abnormalCompleted todayHemoglobin 12.4 g/dL, white cells 4.4 x10^3/uL, ALT 30 U/L: normal
ImagingECG for bradycardia and QTcBaseline; repeat with abnormal electrolytes and before QT-prolonging drugsNot indicatedQTc 436 ms before sertraline; pulse and electrolytes normal; no new QT-prolonging drug
ExaminationRefeeding edema and signs of heart failureEvery visitCompleted todayNo edema
Self-managementExercise and compulsive activityEvery visitCompleted todayAbout an hour of walking a day; no gymnastics
Self-managementMultidisciplinary treatment: CBT-E attendance, dietitian, psychiatryWeekly therapy; dietitian every two weeksCompleted todayWeekly CBT-E; dietitian in person and by video
SurveyPHQ-9At least monthly during acute treatmentCompleted today10, from 16 at intake
SurveySuicide risk reassessment (C-SSRS Since Last Visit and PHQ-9 item 9)Every visitCompleted todayNo thoughts of death for three weeks; PHQ-9 item 9 scored 0. Safety plan reviewed
Medication safetySSRI tolerability check two weeks after starting2 weeks after starting and after each dose changeCompleted todayDone by nurse telephone call two weeks after starting: mild nausea only; no activation or bleeding
Medication safetyAdherence and adverse-effect review; sodium on an SSRIEvery visitCompleted todayNo missed doses; sodium 137 mmol/L
Laboratory25-hydroxyvitamin D after repletionAbout three months after starting, then yearlyDueDue at the next review

Goal progress:

Guideline basis: The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders, Fourth Edition (2023); Medical Management of Restrictive Eating Disorders in Adolescents and Young Adults (position paper) (2022); Eating Disorders: A Guide to Medical Care (AED Medical Care Standards Guide), 4th edition (2021); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders and osteoporosis monographs (2026); VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder (2022); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)

Follow-up: Review in about nine weeks. Next scheduled visit 1894-06-30: twenty-one-week review: weight, mood, the gastroenteritis, and care while travelling. [S]